首页 | 本学科首页   官方微博 | 高级检索  
检索        

吉西他滨联合卡培他滨与顺铂治疗耐药性晚期乳腺癌的近期疗效及不良反应比较
引用本文:谷子.吉西他滨联合卡培他滨与顺铂治疗耐药性晚期乳腺癌的近期疗效及不良反应比较[J].实用医院临床杂志,2014(5):82-85.
作者姓名:谷子
作者单位:成都市第二人民医院急诊外科,四川成都610011
摘    要:目的:比较吉西他滨联合卡培他滨( GC)方案与联合顺铂( GP)方案治疗蒽环类和紫衫类药物耐药晚期乳腺癌的近期疗效、不良反应和生存时间。方法经过紫杉醇蒽环类药物治疗失败的50例乳腺癌患者利用随机数据表分成GC组和GP组各25例,分别给予吉西他滨联合卡培他滨及吉西他滨联合顺铂治疗,均21天为1个周期。化疗2个周期后进行疗效及不良反应评价。结果两组有效率(response rate,RR)及疾病控制率(disease control rate,DCR)差异均无统计学意义(P >0.05);GC组手足综合征的发生率显著高于GP组( P<0.05),其余不良反应两组差异无统计学意义( P >0.05)。结论吉西他滨联合卡培他滨方案治疗晚期乳腺癌疗效及安全性与吉西他滨联合顺铂方案相当,但后者给药更方便。

关 键 词:吉西他滨  卡培他滨  顺铂  乳腺癌  化疗

The comparison of curative effect and adverse reaction of combination of gemicitabine and capecitabine with combination of gemicitabine and cisplatin for advanctd breast cancer patients
GU Zi.The comparison of curative effect and adverse reaction of combination of gemicitabine and capecitabine with combination of gemicitabine and cisplatin for advanctd breast cancer patients[J].Practical Journal of Clinical Medicine,2014(5):82-85.
Authors:GU Zi
Institution:GU Zi (Emergency surgery, The Second People's Hospital of Chengdu , Chengdu 610011, China)
Abstract:Objective To compare the clinical effects and toxicities of gemicitabine plus capecitabine ( GC) regimen versus gemicitabine plus cisplatin ( GP) regimen as first-line chemotherapy in treatment of patients with advances breast cancer who failed in response to anthracycline and taxane .Methods Fifty breast cancer patients who failed in response to anthracycline and /or taxane were randomly assigned to GC or GP group , 25 in each group .Patients in the two groups were treated with GC and GP , respectively .One therapeutic cycle was 21 days.The curative effect and adverse reaction were evaluated after two therapeutic cycles .Results There was no significant difference in the response rate ( RR) and disease control rate ( DCR) between the two groups .The incidence of hand-foot syndrome in the GC group was significantly higher than that in the GP group ( P〈0.05 ) , but no significant difference in other adverse reactions was found between the two group .Conclusion GC regimen as first-line chemotherapy has similar effective and tolerable to GP regimen for breast cancer , but it is more convenient and safe .
Keywords:Gemicitabine  Capecitabine  Cisplatin  Breast cancer  Chemotherapy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号